Sullivan
Microsoft has discontinued support for Internet Explorer. To access the Sullivan website, please install a modern browser like Microsoft Edge or Google Chrome.

Biography

  • Represented Curvature Securities, LLC as placement agent's counsel in connection with a $100 million confidentially marketed public offering of common stock, pre-funded warrants and warrants by CleanCore Solutions, Inc.
  • Represented Curvature Securities, LLC as placement agent's counsel in connection with a PIPE offering up to $21 million of pre-funded warrants in lieu of common stock and milestone warrants by Decoy Therapeutics Inc.
  • Represented Curvature Securities, LLC as placement agent's counsel in connection with a $10 million registered direct offering of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants by Incannex Healthcare Inc.
  • Represented Pelthos Therapeutics as legal counsel in connection with an $18 million financing of senior secured convertible notes.
  • Represented Maxim Group, LLC and Curvature Securities, LLC as sales agents' counsel in connection with a $1.15 billion "at-the-market" facility of common stock by CleanCore Solutions, Inc.
  • Represented Channel Therapeutics Corporation (n/k/a Pelthos Therapeutics Inc.) as legal counsel in connection with its $50 million private placement, completed in conjunction with the merger of a subsidiary of Ligand Pharmaceuticals into Channel Therapeutics.
  • Represented Alexander Capital, L.P. as sales agent's counsel in connection with a $5.795 million "at-the-market" facility of common stock by Blackboxstocks, Inc.
  • Represented Horizon Beverage Group Inc., one of New England’s premier alcohol distributors, in its sale to Southern Glazer’s Wine & Spirits, the world’s preeminent distributor of beverage alcohol.

Matters

  • Represented Curvature Securities, LLC as placement agent's counsel in connection with a $100 million confidentially marketed public offering of common stock, pre-funded warrants and warrants by CleanCore Solutions, Inc.
  • Represented Curvature Securities, LLC as placement agent's counsel in connection with a PIPE offering up to $21 million of pre-funded warrants in lieu of common stock and milestone warrants by Decoy Therapeutics Inc.
  • Represented Curvature Securities, LLC as placement agent's counsel in connection with a $10 million registered direct offering of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants by Incannex Healthcare Inc.
  • Represented Pelthos Therapeutics as legal counsel in connection with an $18 million financing of senior secured convertible notes.
  • Represented Maxim Group, LLC and Curvature Securities, LLC as sales agents' counsel in connection with a $1.15 billion "at-the-market" facility of common stock by CleanCore Solutions, Inc.
  • Represented Channel Therapeutics Corporation (n/k/a Pelthos Therapeutics Inc.) as legal counsel in connection with its $50 million private placement, completed in conjunction with the merger of a subsidiary of Ligand Pharmaceuticals into Channel Therapeutics.
  • Represented Alexander Capital, L.P. as sales agent's counsel in connection with a $5.795 million "at-the-market" facility of common stock by Blackboxstocks, Inc.
  • Represented Horizon Beverage Group Inc., one of New England’s premier alcohol distributors, in its sale to Southern Glazer’s Wine & Spirits, the world’s preeminent distributor of beverage alcohol.

Matters

Horizon Beverage Group, Inc. Acquired by the World’s Preeminent Distributor of Beverage Alcohol

Sullivan represented Horizon Beverage Group Inc., one of New England’s premier alcohol distributors, in its sale to Southern Glazer’s Wine & Spirits, the world’s preeminent distributor of beverage alcohol. The acquisition marks an exciting expansion for Southern Glazer’s, adding Massachusetts and Rhode Island as the 46th and 47th markets in its U.S. footprint, alongside operations in Canada and the Caribbean.

“We are grateful to Horizon’s employees, customers, and partners for so many years of success, and this transition represents an even brighter future for all,” said Bob Epstein, CEO/President at Horizon. “We’re confident that Southern Glazer’s strength and scale will not only support a smooth integration, but also create new opportunities for growth and success.”

“We’re committed to maintaining the exceptional service that Horizon is known for while bringing the added benefits of being part of the Southern Glazer’s family,” added Jim Rubenstein, CEO/Treasurer at Horizon. “This partnership ensures stability and growth for all stakeholders and strengthens our ability to deliver value across the board.”

Lewis N. Segall, Charles E. Chambers Jr., Ida J. Vanto, Sharon G. Leifer, Steven M. Cunningham, Jr. and Christopher C. Curtis

Biotech Focused On Developing Non-Opioid Therapeutics to Alleviate Pain Announced IPO

Sullivan was issuer's counsel for Chromocell Therapeutics Corporation, a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, in their $6.6 million initial public offering of common stock.

The Sullivan team was led by David Danovitch, director of the firm’s Corporate Department, with partners Charles E. Chambers Jr., Aaron Schleicher and associate Brian Hurley. Sullivan has developed a strength in working with entrepreneurial biotech and tech companies in the U.S. and in Israel.

David E. Danovitch, Charles E. Chambers Jr. and Brian P. Hurley